NorthSea Therapeutics has secured $29.3m in series A funding to continue development of treatments for inflammatory and liver diseases.
Novo Seeds, the early-stage investment arm of pharmaceutical group Novo, contributed to a €25m ($29.3m) series A round for Netherlands-based liver disease drug developer NorthSea Therapeutics on Tuesday.
Venture capital firm Forbion led the round with participation from two more VC firms, BioGeneration Ventures and New Science Ventures.
NorthSea is developing structurally engineered fatty acids to treat inflammatory and liver diseases. Its lead candidate, icosabutate, is intended to treat non-alcoholic steatohepatitis (NASH), a liver inflammation disease caused by the build…
